TheraRadar

Pharma Intelligence, Simplified

Company Portfolios →

Guangdong Hengrui Pharmaceutical Co., Ltd

32 active trials across 5 therapeutic areas

32
Active Trials
10
Phase 1
18
Phase 2
7
Phase 3
5
Therapeutic Areas
Portfolio Concentration: 53% of active trials in Immunology

Immunology

17 active / 20 total
Atopic Dermatitis
6 active 2 Ph3
6 total since 2015
Rheumatoid Arthritis
5 active 1 Ph3
6 total since 2015
Lupus
2 active
3 total since 2015
Ankylosing Spondylitis
2 active 1 Ph3
2 total since 2015
Psoriasis
1 active
2 total since 2015
Ulcerative Colitis
1 active
1 total since 2015

Respiratory

10 active / 15 total
Asthma
5 active 2 Ph3
6 total since 2015
Idiopathic Pulmonary Fibrosis
3 active
6 total since 2015
COPD
1 active
2 total since 2015
Allergic Rhinitis
1 active
1 total since 2015

Oncology

1 active / 1 total
Solid Tumor (Advanced)
1 active
1 total since 2015

Rare Disease

1 active / 1 total
Immune Thrombocytopenia
1 active
1 total since 2015

Cardiovascular

0 active / 1 total
Atrial Fibrillation
0 active
1 total since 2015

Click an indication to see competitive landscape (all sponsors in that indication).

Data: ClinicalTrials.gov (2015+)